Aamir Akbarali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aamir Akbarali has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Alexey V. Petukhov
NTU Sirius, Sochi, Russia
1 shared publicationAnastasia R. Goloudina
INSERM UMR1231, LipSTIC, University of Burgundy Franche-Comté, Dijon, France
1 shared publicationBernhard Ryffel
INEM, Experimental and Molecular Immunology and Neurogenetics, University of Orléans, CNRS, UMRP735, Orléans, France
1 shared publication- Bogdan B. Grigorash
Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS, INSERM, Université Côte d'Azur, Nice, France
1 shared publication Burhan Uyanik
INSERM UMR1231, LipSTIC, University of Burgundy Franche-Comté, Dijon, France
1 shared publication- Carmen Garrido
FIBAO, Complejo Hospitalario de Jaén, Jaén, Spain
1 shared publication
Latest Publications
- Open Access
- 15 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses
PPM1D/Wip1 is a negative regulator of the tumor suppressor p53 and is overexpressed in several human solid tumors. Recent reports associate gain-of-function mutations of PPM1D in immune cells with worse outcomes for several human cancers. Here we show that mice with genetic knockout of Ppm1d or with conditional knockout of Ppm1d in the hematopoietic system, in myeloid cells, or in neutrophils all display significantly reduced growth of syngeneic melanoma or lung carcinoma tumors. Ppm1d knockout neutrophils infiltrate tumors extensively. Chemical inhibition of Wip1 in human or mouse neutrophils increases anti-tumor phenotypes, p53-dependent expression of co-stimulatory ligands, and proliferation of co-cultured cytotoxic T cells. These results suggest that inhibition of Wip1 in neutrophils enhances immune anti-tumor responses.
- 15 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Open AccessInhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses
PPM1D/Wip1 is a negative regulator of the tumor suppressor p53 and is overexpressed in several human solid tumors. Recent reports associate gain-of-function mutations of PPM1D in immune cells with worse outcomes for several human cancers. Here we show that mice with genetic knockout of Ppm1d or with conditional knockout of Ppm1d in the hematopoietic system, in myeloid cells, or in neutrophils all display significantly reduced growth of syngeneic melanoma or lung carcinoma tumors. Ppm1d knockout neutrophils infiltrate tumors extensively. Chemical inhibition of Wip1 in human or mouse neutrophils increases anti-tumor phenotypes, p53-dependent expression of co-stimulatory ligands, and proliferation of co-cultured cytotoxic T cells. These results suggest that inhibition of Wip1 in neutrophils enhances immune anti-tumor responses.